Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Effective Anti‐metastatic Melanoma Vaccination With Tumor Cells Transfected With MHC Genes And/or Infected With Newcastle Disease Virus (NDV)

D. Plaksin, A. Porgador, E. Vadai, M. Feldman, V. Schirrmacher, L. Eisenbach
Published 1994 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The therapeutic efficacy of active immunization with B16‐F10.9 melanoma cells transfected with syngeneic major histocompatibility complex (MHC) class‐l genes, modified by infection with Newcastle Disease virus (NDV) or modified by both treatments, was compared. B16‐F10.9 tumor‐bearing mice were treated at various stages of tumor growth and metastasis with irradiated, modified tumor‐cell vaccines. Irradiated tumor cells and H‐2Db transfectants did not stimulate anti‐tumor immunity while H‐2Kb transfectants and NDV‐modified F10.9 cells showing low and high expression of MHC class‐l genes efficiently prevented metastasis of small established tumors. NDV‐modified parental‐cell vaccines functioned optimally and improved overall survival by about 60%, also at early stages of metastasis establishment. A synergistic effect of H‐2Kb expression and virus modification on rejection of micrometastases was observed in mice bearing advanced tumors. Postoperative vaccination of mice carrying multiple metastases with NDV‐modified vaccines caused significant, but incomplete, reduction of metastatic tumor load. The therapeutic effect of NDV‐modified tumor vaccines was dependent on multiple immune mechanisms. Depletion of CD8, CD4 or NK cells by in vivo treatment with monoclonal antibodies reversed the immunotherapeutic effects of the vaccine. Thus, tumor xenogenization and gene modification may act synergistically to vaccinate against advanced tumors, while single modalities can effectively vaccinate against metastasis at early stages of tumor growth.
This paper references
10.1038/312548A0
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
S. Cobbold (1984)
10.1002/IJC.2910530320
Anti‐metastatic vaccination of tumor‐bearing mice with il‐2‐gene‐inserted tumor cells
A. Porgador (1993)
10.1089/HYB.1984.3.301
Establishment of monoclonal anti-Nk-1.1 antibody.
G. Koo (1984)
10.1111/j.1744-313X.1989.tb00475.x
H‐2Kb TRANSFECTION OF B16 MELANOMA CELLS RESULTS IN REDUCED TUMOURIGENICITY AND METASTATIC COMPETENCE
A. Porgador (1989)
10.1016/S0065-230X(08)60899-4
Viral xenogenization of intact tumor cells.
H. Kobayashi (1979)
10.1016/0304-419X(74)90007-9
Viruses as immunological adjuvants in cancer.
J. Lindemann (1974)
10.1002/EJI.1830180803
Modification of tumor cells by a low dose of Newcastle Disease Virus.
Paul Von Hoegen (1989)
10.1002/IJC.2910520517
H‐2Db gene transfer into highly metastatic D122 cells results in tumor rejection in allogeneic recipients, but does not affect metastasis in syngeneic recipients. Implications for mechanisms of allorejection
D. Plaksin (1992)
Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines.
D. Wilde (1983)
10.1002/1097-0142(19830901)52:5<856::AID-CNCR2820520519>3.0.CO;2-4
A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate
W. Cassel (1983)
10.1038/icb.1993.36
Tumour‐Specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens
V. Schirrmacher (1993)
10.1073/PNAS.85.12.4463
Reversal of the metastatic phenotype in Lewis lung carcinoma cells after transfection with syngeneic H-2Kb gene.
D. Plaksin (1988)
Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells.
A. Porgador (1992)
Immunotherapy for Vulvar Carcinoma With Virus-Modified Homologous Extracts
R. Freedman (1983)
10.1016/0008-8749(90)90302-8
Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta.
P. Hoegen (1990)
10.1089/HYB.1993.12.543
Tumor cell vaccination for gynecological tumors.
V. Möbus (1993)
10.1002/EJI.1830231032
Viral hemagglutinin augments peptide‐specific cytotoxic T cell responses
C. Ertel (1993)
10.1093/JNCI/54.4.997
Inhibition of metastasis in rats immunized with xenogenized autologous tumor cells after excision of the primary tumor.
H. Kobayashi (1975)
Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells.
A. Porgador (1993)
10.1002/1097-0142(19901001)66:7<1517::AID-CNCR2820660714>3.0.CO;2-I
Postoperative active specific immunization in colorectal cancer patients with virus‐modified autologous tumor‐cell vaccine. First clinical results with tumor‐cell vaccines modified with live but avirulent newcastle disease virus
Wolfram Bohle (1990)



This paper is referenced by
10.1007/s00005-008-0047-9
Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers
J. G. Sinkovics (2008)
10.1038/sj.cgt.7700109
Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells
C. Termeer (2000)
Acute Leukemias VII. Experimental Approaches and Novel Therapies. International Symposium. Munster, Germany, February 22-26, 1997. Abstracts.
W. Hiddemann (1997)
10.1038/cgt.2010.36
Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies
F. Alcayaga-Miranda (2010)
10.1007/s002620050380
Variant mouse lymphoma cells with modified response to interferon demonstrate enhanced immunogenicity
N. Mador (1997)
10.2217/fmb.12.4
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.
D. Zamarin (2012)
10.1007/978-1-59745-561-9_30
Newcastle Disease Virus: A Promising Vector for Viral Therapy, Immune Therapy, and Gene Therapy of Cancer
V. Schirrmacher (2009)
The Effects of Levamisole Hydrochloride and LaSota Strain of Newcastle Disease Virus in the Treatment of Cancer
Abdul Ameer Oda Ismail (2008)
Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
C. Haas (1998)
Vaccination with Melanoma Cells Infected with Recombinant Newcastle Disease Virus Suppresses Tumor Metastasis
ShigefumiKishida (2018)
10.1007/BF01218359
Biotherapy of cancer
V. Schirrmacher (2005)
10.1111/j.1349-7006.1999.tb00687.x
Effectiveness of a Simply Designed Tumor Vaccine in Prevention of Malignant Melanoma Development
S. Novakovic (1999)
10.3389/fonc.2019.00436
STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
Xiaoyan Shao (2019)
10.1007/s002620050570
Induction of antitumor immunity after cure of pulmonary metastases, using staphylococcal enterotoxin B and bispecific antibody
D. Rice (1999)
10.1002/(SICI)1098-2388(199806)14:4<328::AID-SSU9>3.0.CO;2-4
Overview of melanoma vaccines: active specific immunotherapy for melanoma patients.
D. Ollila (1998)
10.1089/JIR.1996.16.805
Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages.
C. Fleischmann (1996)
Therapeutic cancer vaccines.
B. Acres (2004)
An overview on the development of newcastle disease virus as an anti-cancer therapy.
A. R. Omar (2003)
10.1016/S0753-3322(00)80070-0
Use of xenogenized (modified) tumor cells for treatment in experimental tumor and in human neoplasia.
S. Benefraim (2000)
Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
V. Schirrmacher (1997)
10.1007/978-1-4615-6349-5_2
Post-bone marrow transplant use of immunotherapy.
U. Verma (1997)
10.1038/sj.pcan.4500278
Adenovirus-mediated gene transfer in dog prostate: a preclinical study of a relevant model system for gene therapy of human prostatic cancer
M. Andrawiss (1999)
10.1007/978-3-642-80071-9_12
Immunotherapy of metastases.
V. Schirrmacher (1996)
10.1007/978-1-4615-5357-1_41
Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy.
V. Schirrmacher (1998)
10.1017/S0829320100006244
Les Organismes génétiquement modifiés (OGM) et la société: Le principe de précaution, une norme de régulation du débat social?
S. Manga (2000)
10.1517/14712598.5.8.1051
T cell-mediated immunotherapy of metastases: state of the art in 2005
V. Schirrmacher (2005)
10.1038/sj.cgt.7700048
An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules
C. Haas (1999)
10.1016/S1278-3218(99)80016-X
Prise en charge du mélanome cutané
L Thomas (1998)
10.1007/s00262-004-0602-0
Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory
V. Schirrmacher (2004)
10.1038/SJ.MT.6300039
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.
A. Power (2007)
10.7488/ERA/523
Molecular mechanisms of oncolytic properties of Newcastle disease virus (NDV) in human cancer cells
Archana Chandrabhan Jadhav (2020)
10.1023/A:1011577632619
Transfection of the Newcastle Disease Virus Hemagglutinin-Neuraminidase Gene into Murine Myeloma Cells for Induction of Host-versus-Tumor Immune Response
N. V. Risinskaya (2004)
See more
Semantic Scholar Logo Some data provided by SemanticScholar